Rubius Therapeutics, Inc. (RUBY)
Rubius Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $0.06, up 2.70% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of 0.0%. Its beta of 2.21 implies it has historically moved more than the broad market.
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics, Inc. is most often compared with the following Healthcare names: